Howard Horn, serving as the Chief Financial Officer for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), completed a share transaction on July 1, 2026. The execution involved the sale of 4,698 shares of the company’s common stock. The total financial value attributed to this specific divestment stands at $155,644. The transaction was priced at $33.13 per share.
Following the execution of this sale, Horn’s direct ownership position in the company’s common stock totals 100,991 shares. This specific holding count includes previously disclosed shares associated with Restricted Stock Units (RSUs) granted to Horn. These units remain subject to established vesting conditions. The sale was executed in accordance with a Rule 10b5-1 trading plan, a standard mechanism for pre-arranged executive transactions.
Market data indicates notable momentum in Ultragenyx stock performance. Shares are currently trading at $34.04. This price point reflects a 48% gain over the preceding six-month period and a 46% return for the year-to-date timeframe. Analysis from InvestingPro suggests that Ultragenyx may be undervalued at current market levels. The analysis cites a Fair Value metric that implies potential upside. The company has not yet achieved profitability over the last twelve months. This financial status is highlighted within a comprehensive Pro Research Report designed to translate complex financial data into actionable intelligence for investors.
Ultragenyx recently reported its financial results for the first quarter of 2026. The report revealed a net loss of $1.84 per share. This figure fell below analyst expectations, which had projected a loss of $1.46 per share. Revenue for the quarter was recorded at $136 million. This amount also missed the forecasted figure of $160.69 million. Despite these misses, the company reaffirmed its full-year revenue guidance.
In a separate development, Cantor Fitzgerald adjusted its outlook for Ultragenyx shares. The firm raised its price target to $96, an increase from a previous target of $84. The firm maintained an Overweight rating on the stock. This adjustment was influenced by an increased probability of success for GTX-102, a treatment for Angelman syndrome. Additionally, Ultragenyx held its annual meeting. Shareholders approved the election of three Class I directors and several key proposals. These directors will serve until the 2029 annual meeting or until successors are duly elected.